•
Dec 31, 2024
Viking Therapeutics Q4 2024 Earnings Report
Expected Revenue:$0
Expected EPS:-$0.28
12.0% YoY
Key Takeaways
Viking Therapeutics reported a net loss of $35.4 million, or $0.32 per share, for the fourth quarter of 2024. The company's research and development expenses were $31.0 million, and general and administrative expenses were $15.3 million. Viking ended the year with a strong cash position of $903 million.
Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25
Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway
Strong Year-End Cash Position of $903 Million
VK0214 in X-ALD Demonstrates Improvement in Key Biomarker
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking expects to initiate Phase 3 trials evaluating subcutaneous VK2735 in obesity in 2Q25 and is currently planning to file an IND application for the DACRA program later this year.